Subscribe

Your FREE subscription will give you access to articles, research reports, Biopharma CEO Confidence quarterly reports and much more!

Biopharmaceutical Consulting

The Biopharmaceutical practice at Kineticos assists growth-oriented pharmaceutical and biotech companies realize their commercial potential at the corporate, portfolio and product levels.

The Biopharmaceutical practice at Kineticos supports clients across three service areas including:

Corporate Strategy

Our Corporate Strategy services combine our in-depth experience and industry knowledge with benchmarks and competitive analysis to help biopharmaceutical companies make critical strategic, financial, and, business development decisions.

Corporate Development

Our Corporate Development services will support and enable biopharmaceutical companies to assess potential opportunities and complete transactions to drive business.

Commercial Strategy

Our Commercial Strategy services help biopharmaceutical companies maximize the commercial value of their products across all phases of the product lifecycle.

Call us today at 888-986-6960 or send an email to Discover How We Can Elevate Your Business

Ready to learn more about Kineticos successes? Click the Tabs Below for Biopharmaceutical Practice Case Studies, White Papers and Articles, and Blog

 

Case Studies
Articles
Blog
  • Diagnostics Partnering Support

    Situation: An emerging oncology diagnostics company was in need of a Business Development strategy and retained Kineticos to develop such

     

    Read this Case Study

  • Oncology Commercial Assessment – Melanoma

    Situation: A clinical-stage oncology company with a potentially ground-breaking technology requested Kineticos to help determine which tumor type(s) had the

     

    Read this Case Study

  • Business Development & Licensing

    Situation: An innovative oncology diagnostics company retained Kineticos to assist in developing their pitch deck, as well as developing and

     

    Read this Case Study

  • Product Search

    Situation: A drug delivery technology company identified an opportunity to generate additional revenue by acquiring products to further develop and

     

    Read this Case Study

  • Portfolio Prioritization – Oncology

    Situation: A publicly traded Oncology company with 3 technology platforms and limited resources was in need of narrowing their focus. 

     

    Read this Case Study

  • Commercial Assessment

    Situation: A mid-sized biotech company evaluating their Phase II Metabolic asset requested that Kineticos provide a commercial and financial assessment

     

    Read this Case Study

  • Immuno-Oncology: In the Goldilocks Zone or Over-Invested?

    Written by Steve Buckanavage, Operating Executive, Kineticos It wasn’t that long ago that cancer was defined by the location in

     

    Read this Article

  • Staying the Course

    Written by Mark Osterman, Senior Vice President, Kineticos Kineticos recently announced Q4 2015 results of the Biopharma CEO Confidence Index,

     

    Read this Article

  • Cell and Gene Therapies: The Path to Commercialization

    Article Preview Regenerative Medicine holds enormous potential for treating and ameliorating many chronic conditions for which we do not yet

     

    Read this Article

  • Bridges and Barriers to Advancing CAR T Therapy

    One result of the Oncology explosion over the past 10 years has been the advent of CAR T therapy. In

     

    Read this Article

  • Growth by Acquisition in Life Sciences: Do You Have a Plan?

    Article Preview As the life sciences landscape continually changes, growth by acquisition has become increasingly common. Recent deals, such as

     

    Read this Blog Post

  • R&D Revolutionaries: Why the Actavis/Allergan Deal Takes a Stand for Biopharma’s True Roots in Innovation

    James Forte of Kineticos takes an in-depth look at the recent Actavis/Allergan deal including the role R&D innovation played in shaping the deal’s outcome. Let’s be candid. It’s been awhile since any biopharma company was able to claim R&D as a core competency with a straight face. Biopharma’s R&D efforts have long been challenged, and rightly so given its output, but the Actavis/Allergan deal shows that the right investment in R&D can revolutionize a business. Could efficient R&D be the new definition of innovation?

     

    Read this Blog Post

  • Merck KGaA and Bayer Choose Opposite Strategies

    Article Preview Europe’s two largest chemical and drug conglomerates are changing course in starkly opposite ways. As reported in recent

     

    Read this Blog Post

  • Foundation Medicine and Clovis Expand Partnership

    Article Preview In April 2014, Foundation Medicine and Clovis Oncology announced the expansion of their partnership by developing a companion

     

    Read this Blog Post

  • Role of Companion Diagnostics in Immuno-oncology Race Unfolding

    Article Preview Important oncology events, including ASCO and ESMO, have recently displayed the fruits of the huge investment drug companies

     

    Read this Blog Post

  • Bayer to Divest Plastics Unit to Improve R&D, Acquisition Capacity

    Article Preview As reported by Bloomberg and the Wall Street Journal, Bayer is expected to announce plans to sell its

     

    Read this Blog Post


Contact Us Today to Discover How We Can Elevate Your Business Our Strategy Consulting Services Are Designed to Enhance Your Value

Contact Us Today
Top